

BMJ Open Methods for evaluation of corneal nerve fibres in diabetes mellitus by in vivo confocal microscopy: a scoping review protocol

Siv Aaseth Sandvik ¹, Vibeke Sundling ¹, Neil Lagali ²

To cite: Sandvik SA, Sundling V, Lagali N. Methods for evaluation of corneal nerve fibres in diabetes mellitus by in vivo confocal microscopy: a scoping review protocol. *BMJ Open* 2023;**13**:e070017. doi:10.1136/bmjopen-2022-070017

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-070017>).

Received 16 November 2022
Accepted 23 March 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Optometry, Radiology and Lighting Design, University of South-Eastern Norway, Kongsberg, Norway
²Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Correspondence to
Siv Aaseth Sandvik;
siv.a.sandvik@usn.no

ABSTRACT

Introduction Globally, 422 million people have diabetes. Late complications of diabetes are blindness, kidney failure, heart attack, stroke and lower limb amputation. The prevalence of diabetic peripheral neuropathy and diabetic retinopathy is 50% and 35%, respectively. In vivo confocal microscopy (IVCM) is a rapid, non-invasive method to evaluate subbasal corneal nerve fibres, which are small fibres of the peripheral nervous system. Corneal nerve fibre changes can be a marker of diabetic peripheral neuropathy. There is currently no gold-standard procedure for IVCM imaging, image processing or quantitative analysis of the corneal nerve fibres in the subbasal plexus. This protocol describes a scoping review to map, summarise and critically evaluate current methods used with IVCM evaluation in people with diabetes mellitus.

Methods The scoping review will follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for scoping review. A comprehensive search of the literature will be conducted in MEDLINE, Embase, Cochrane, Scopus and Web of Science. The search strategy will include terms related to IVCM, diabetes and corneal nerve fibres. We will set inclusion and exclusion criteria prior to the search, and two reviewers will screen titles and abstracts independently. One reviewer will full text read eligible articles and chart data from the studies. A descriptive summary of the methods used in imaging, image processing and quantitative analysis of peripheral corneal nerve fibres by IVCM will be written.

Ethics and dissemination Ethical approval is not required since this is a scoping review based on previously published articles. The findings will be published in a scientific peer-reviewed journal.

BACKGROUND

According to the WHO, about 422 million people had diabetes in 2014. Late complications of diabetes are blindness, kidney failure, heart attack, stroke and lower limb amputation.¹ Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, represented in half of the patients with diabetes.^{2 3} Globally, as many as 35% (93 million people) have some degree of diabetic retinopathy

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Protocol guidelines and the updated JBI guidelines for scoping review by Peters *et al*.
- ⇒ Report the results according to the PRISMA extension for Scoping Reviews checklist.
- ⇒ Professional librarian conducted the search.
- ⇒ Not meta-analysis.

(DR) and 5%–10% of people with diabetes has sight-threatening stages of retinopathy and diabetic macular oedema (DME) (28 million people).⁴

DR and DME are leading causes of blindness and visual impairment in the working-age population.^{5 6} Reduced vision leads to everyday challenges related to tasks such as reading and moving around outside and is associated with psychosocial outcomes such as higher frequency of depression and depressive symptoms.⁷ DPN is also associated with sensory loss and weakness in muscles.³ It leads to posture, gait and sensation loss challenges,⁸ as well as foot ulcers.⁹ DPN in its late stages can even lead to amputation,¹⁰ reduced sleep quality and depression.¹¹

The eye provides unique opportunity to evaluate neurodegenerative changes in the cornea and retina. In vivo confocal microscopy (IVCM) has the ability to examine the corneal nerves with high resolution and extreme precision.¹² It is a rapid, non-invasive method to analyse corneal morphology and quantify corneal nerve density, nerve length, tortuosity and thickness.¹³ However, studies are performed with three different types of confocal microscopy based on different light scanning principles. Tandem scanning uses white light and a rotating disc, slit scanning uses white light and a moving linear slit, and laser scanning uses a focused laser spot that

is raster scanned, to illuminate and collect light from the structure in the cornea.^{12 14} The light source used and illumination area has impact on the quality of the images regarding contrast and resolution.^{15 16}

Stem *et al* suggest that pathology in corneal nerve fibres seems to manifest before peripheral neuropathy,¹⁷ while others have reported that corneal nerve loss may predict incident neuropathy and progresses with DPN severity.¹⁸

There is evidence that corneal nerve fibre changes also manifest before visible DR, and may worsen progressively with increasing severity of DR.¹⁹ In more severe DR stages, DPN is also more pronounced.²⁰ Several studies have explored the associations between corneal nerve fibres and DR^{19 21–24} and between corneal nerve fibres and DPN.^{18 25 26} Bitirgiren (2014),¹⁹ Petropoulos (2015),²² and Schiano Lomoriello (2019)²³ found reduced corneal nerve fibre length (CNFL), corneal nerve fibre density (CNFD) and corneal nerve branch density (CNBD) in those with diabetes without DR compared with healthy controls. Nitoda (2012)²¹ and Srinivasan (2017)²⁴ found differences in CNFL with different degrees and classifications of DR compared with healthy controls. The meta-analysis by Jiang *et al*,²⁵ evaluating 1680 participants, concluded that CNFL, CNFD and CNBD were significantly reduced in patients with DPN compared with healthy controls.²⁵ However, that analysis also concluded that comparing studies is challenging based on the different instrumentation and analysis methods used across studies.

CNFL is currently considered to be the most reliable surrogate parameter for quantifying corneal small fibre loss and hence early DPN.^{20 27–31} An upper and lower value of 15.3 mm/mm² and 8.6 mm/mm², respectively, have been found to rule in and out diabetic sensorimotor polyneuropathy (DSPN), with an 88% specificity and 88% sensitivity in a total cohort of 998 people with diabetes mellitus (DM), from five centres.³¹ However, defining thresholds is limited based on the sample, type of diabetes, sample size and measurement errors that limit the precision.²⁷ Hafner *et al* suggest that ophthalmologists have the opportunity to play a critical role in the early diagnosis of DPN. They also point out the need for further understanding of the complex and divergent pathophysiological processes of diabetes to facilitate early identification to prevent vision-threatening retinal disease and advanced neuropathy.²⁰

Changes in the corneal nerves may proceed reduced corneal sensitivity in people with diabetes.^{32 33} A reduction in CNFD³² and CNFL has been found in people with DM.³⁴

There are some challenges to overcome before IVCN can be used for broader clinical use. First, the corneal nerve parameters may differ depending on the corneal region imaged and used for analysis; therefore, a sampling bias exists. The corneal nerve density is significantly higher in the inferior whorl region, located 1–1.5 mm inferior nasal to corneal apex, compared with the central cornea.³⁵ Also, there is a higher nerve fibre density in central cornea compared with the periphery.³⁶

Second, each image represents a small field of view, where less than 1% (400×400 μm) of the total subbasal nerve plexus is included.³⁷ Studies have tried to overcome this by collecting multiple images for analysis. Vagenas *et al* stated that five images, not overlapping more than 20%, give an average that was within 13% of the true mean 80% of the time. By increasing to eight randomly chosen images, still not overlapping more than 20%, this gives an average that was within 30% of the true mean 95% of the time.³⁸ Badian *et al* stated that the CNFL was underestimated by 34% in the central region compared with a wide-field mosaic generation of the subbasal nerve plexus (SBNP) for 90% of eyes with type 2 DM.³⁹ They suggest larger areas of the corneal SBNP should be evaluated to improve the diagnostic sensitivity and specificity and to confirm other studies that found a significant reduction in people with type 2 DM.³⁹ Therefore, it is essential to consider the image acquisition area used in different studies when sampling the raw material to evaluate sampling biases when comparing studies.

Third, the quality of the images are factors to consider: the instrument used has an impact on the quality, image depth, enhancement in software used to influence the visibility of the nerves, and repeatability and reliability of measurement methods.³⁷ The experience level of the clinician will also affect the image quality.

Fourth, the methods of image analysis are also essential. Different studies report the use of different software for image analysis. Both software-associated wide-field imaging and algorithms based on artificial intelligence have been explored to achieve efficient screening.¹⁸ Manual analysis is more time-consuming and subject to reduced inter and intrarater variability.⁴⁰ When manually analysing the sample, it is also essential to mask the observer to the groups with and without diabetes to avoid performance biases.

Automated analysis reduces the time for analysis and interobserver/intraobserver variability. According to Herrera-Pereda *et al* computerised analysis is still not efficient and validated for clinical practice, however, Lagali *et al* showed in 2017 that automated nerve detection and tracing algorithms were fast and could be used in the clinic.^{34 40}

There is currently no gold-standard procedure for IVCN for imaging, image processing and quantitative analysis of the corneal nerve fibres in the subbasal plexus. However, Petropoulos *et al* state that generally 5–8 non-overlapping images from the apical cornea and two from the inferior whorl should be used to assess DPN.¹⁸ Given, however, the widely varying methodologies and practices inherent in the literature, we believe that it is useful for future research and clinical care to perform a detailed scoping review to map and summarise methods used in IVCN evaluation of corneal nerve fibres in DM.

METHODS

The review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Protocol guidelines and the updated Joanna Briggs Institute's (JBI) guidelines for scoping review by Peters *et al*⁴¹ and report the results according to the PRISMA extension for Scoping Reviews checklist.⁴² This paper is the protocol for the scoping review.

Identifying the research question

The scoping review aims to map and summarise methods used in IVCN evaluation of corneal nerve fibres in people with DM, and critically review the methodology for imaging acquisition, image processing and quantitative analyses of peripheral corneal nerve fibres by IVCN in people with DM and relevant control groups. The goal is to objectively identify low bias, reproducible, and appropriate imaging techniques, image processing and image analysis methods for research and clinical practice.

A preliminary search for existing reviews in PubMed, Cochrane database for systematic review and in PROSPERO (January 2022) did not identify any published review on the methodology using IVCN to evaluate corneal nerve fibres in the SBNP in the context of diabetes.

We suggest evidence of multiple limitations and heterogeneity in the sampling procedure, selection of images and statistical analysis reported in previous studies. We aim to further explore these aspects by addressing the following underlying research questions:

1. What type of diabetes has been evaluated and using which diagnostic criteria?
2. What are the methodology and image techniques used in IVCN examination of nerves in people with DM?
3. What data reduction methods are used to obtain a relevant and representative raw image dataset?
4. What methods are used to process images and extract quantitative nerve parameter data from the raw image dataset?
5. How are the extracted images analysed? Based on single image, multiple single images or merged images?
6. What outcome measures and quantitative outcome values (SD, mean, median, IQR) are reported for corneal nerve parameters in subjects with diabetes and healthy controls?
7. What statistical analyses are performed to compare corneal peripheral nerves across subject groups, and are these appropriate and do the studies have adequate statistical power?
8. How can we improve the quality and reproducibility of methodology and reduce bias in future studies investigating the peripheral corneal nerves with IVCN?

Identifying relevant studies

A three-step search strategy will be used to identify evidence in the scientific literature.

First, the databases (1) MEDLINE, (2) Embase, (3) Cochrane, (4) Scopus and (5) Web of Science will be used

to search for studies involving IVCN and corneal nerve fibres in people with DM. These are databases with references in (1) health sciences and biomedical research, (2) pharmacology, general public health, substance abuse, environmental and occupational medicine, (3) research results from health research, (4) a wide variety of disciplines and (5) all academic fields of the world's most cited scholarly journals in the Sciences, Social Sciences and Arts and Humanities. We will develop a full search strategy for each database together with an academic librarian who will perform the search. The search will be conducted using the keywords (Thesaurus/Medical subject headings (MESH) and text words (keywords)) for "in vivo confocal microscopy" AND cornea AND ("diabetes mellitus"). The entire search term is provided in online supplemental file 1. We will search the databases from inception, including papers published in English, German and the Scandinavian languages. Where relevant, authors will be contacted to identify additional sources. Second, additional text words in the title and abstract and index terms used to describe the articles will be included in the second search in MEDLINE, Embase, Cochrane, Scopus and Web of Science using all identified keywords and index terms. Third, we will search the reference list of papers, including full-text reading, for additional sources.

Inclusion criteria: Empirical and research articles based on humans >18 years of age and articles published in peer-reviewed journals will be included. We will include randomised controlled trials, controlled trials, intervention studies, experimental studies, quasi-experimental studies, observational studies with a control group, within-subject/repeated measures studies and case-control studies, study protocols and observational studies without a control group. Qualitative studies, literature reviews, commentaries, letters, editorials, conference papers or proceedings, opinion or discussion papers, dissertations/thesis, abstracts/presentations, grey literature and brief reports will be excluded.

Study selection

The search result will be imported to Endnote for removal of duplicate studies and then exported to Rayyan⁴³ for screening of titles, keywords and abstracts. We will complete the screening and select studies in two steps.

First, two independent reviewers will screen the title and abstracts to identify eligible studies. A sample of 25 studies will be screened regarding title and abstract to determine the inter-rater agreement, and a 75% agreement should be met before working further. In cases of disagreement about inclusion, the review authors will discuss. If a consensus is not achieved, a third reviewer will be consulted to make the decision.

In the next step, one reviewer will screen the full text of the potentially eligible studies. If questions arise on inclusion criteria is met, a second author will be consulted to discuss and make a decision. A PRISMA flow chart will document the study selection procedure.

Charting the data

Data will be extracted, and a descriptive or tabular summary of the methods used in imaging acquisition, image processing and quantitative analysis of peripheral corneal nerve fibres by IVCN will be written. Extracted data will fall within the following main domains: publication details, demographics of the participants and outcome variables. In addition, summary tables will include essential information about the source; author(s), title, year of publication, journal, study design, aim, demographics and sample size. Furthermore, we will chart the studies' inclusion and exclusion criteria, imaging instrumentation, imaging procedures, image sampling and extraction procedures, outcome variables and outcome findings and the study's conclusion and implications. If necessary, the data extraction form will be updated during the review process as this is seen as a process of improvement. Two reviewers have piloted the data extraction form (online supplemental file 2) according to the recommendations from Peters *et al.*⁴¹

Collating, summarising and reporting the results

We will collate the results and summarise IVCN imaging and image analysis methods, provide an overview of the quality of imaging techniques and image analysis methods, and identify potential best practices, limitations and areas for further improvements. From the included studies and through the use of standardised tools such as AXIS, ROBBIN and ROB2, the authors will provide a descriptive analysis of the bias that may be presented in the different studies.

Patient and public involvement statement

No patients or public were directly involved in this study's concept, design and planning.

Acknowledgements We acknowledge the librarian Jana Myrvold and Anna Skjæret Stenhammer for their contribution to development of the search strategy and performing the search in MEDLINE, Embase, Cochrane, Scopus and Web of Science. Guarantor: University of South-Eastern Norway.

Contributors The authors confirm contribution to the paper as follows: study conceptualisation; VS and NL. SAS wrote the original draft, and SAS, VS and NL reviewed and edited the draft, and VS was the primary investigator and supervised SAS in writing the protocol. All authors approved the protocol.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Siv Aaseth Sandvik <http://orcid.org/0000-0003-2270-313X>

Vibeke Sundling <http://orcid.org/0000-0002-9567-239X>

Neil Lagali <http://orcid.org/0000-0003-1079-4361>

REFERENCES

- World Health Organization. Diabetes. Available: https://www.who.int/health-topics/diabetes#tab=tab_1 [Accessed 17 Jan 2022].
- Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. *J Diabetes Investig* 2017;8:646–55.
- Yan A, Issar T, Tummanapalli SS, *et al.* Relationship between corneal confocal microscopy and markers of peripheral nerve structure and function in type 2 diabetes. *Diabet Med* 2020;37:326–34.
- Wong TY, Cheung CMG, Larsen M, *et al.* Diabetic retinopathy. *Nat Rev Dis Primers* 2016;2:16012.
- Bourne RRA, Jonas JB, Bron AM, *et al.* Prevalence and causes of vision loss in high-income countries and in eastern and central Europe in 2015: magnitude, temporal trends and projections. *Br J Ophthalmol* 2018;102:575–85.
- Kilstad HN, Sjølie AK, Gøransson L, *et al.* Prevalence of diabetic retinopathy in Norway: report from a screening study. *Acta Ophthalmol* 2012;90:609–12.
- Khoo K, Man REK, Rees G, *et al.* The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. *Qual Life Res* 2019;28:2017–39.
- Domínguez-Muñoz FJ, Adsuar JC, Villafaina S, *et al.* Test-retest reliability of vibration perception threshold test in people with type 2 diabetes mellitus. *Int J Environ Res Public Health* 2020;17:1773.
- Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, *et al.* The global burden of diabetic foot disease. *Lancet* 2005;366:1719–24.
- Pearce I, Simó R, Lövestam-Adrian M, *et al.* Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. *Diabetes Obes Metab* 2019;21:467–78.
- Argoff CE, Cole BE, Fishbain DA, *et al.* Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. *Mayo Clin Proc* 2006;81:S3–11.
- Roszkowska AM, Licitra C, Tumminello G, *et al.* Corneal nerves in diabetes—the role of the in vivo corneal confocal microscopy of the subbasal nerve plexus in the assessment of peripheral small fiber neuropathy. *Surv Ophthalmol* 2021;66:493–513.
- Markoulli M, Flanagan J, Tummanapalli SS, *et al.* The impact of diabetes on corneal nerve morphology and ocular surface integrity. *Ocul Surf* 2018;16:45–57.
- Lagali N, Peebo BB, Germundsson J, *et al.* Laser-scanning in vivo confocal microscopy of the cornea: imaging and analysis methods for preclinical and clinical applications. *IntechOpen* 2013.
- Patel DV, McGhee CNJ. Contemporary in vivo confocal microscopy of the living human cornea using white light and laser scanning techniques: a major review. *Clin Exp Ophthalmol* 2007;35:71–88.
- Guthoff RF, Zhivov A, Stachs O. In vivo confocal microscopy, an inner vision of the cornea—a major review. *Clin Exp Ophthalmol* 2009;37:100–17.
- Stem MS, Hussain M, Lentz SI, *et al.* Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. *J Diabetes Complications* 2014;28:658–61.
- Petropoulos IN, Ponirakis G, Ferdousi M, *et al.* Corneal confocal microscopy: a biomarker for diabetic peripheral neuropathy. *Clin Ther* 2021;43:1457–75.
- Bitirgen G, Ozkagnici A, Malik RA, *et al.* Corneal nerve fibre damage precedes diabetic retinopathy in patients with type 2 diabetes mellitus. *Diabet Med* 2014;31:431–8.
- Hafner J, Zadrazil M, Grisold A, *et al.* Retinal and corneal neurodegeneration and their association with systemic signs of peripheral neuropathy in type 2 diabetes. *Am J Ophthalmol* 2020;209:197–205.
- Nitoda E, Kallinikos P, Pallikaris A, *et al.* Correlation of diabetic retinopathy and corneal neuropathy using confocal microscopy. *Curr Eye Res* 2012;37:898–906.
- Petropoulos IN, Green P, Chan AWS, *et al.* Corneal confocal microscopy detects neuropathy in patients with type 1

- diabetes without retinopathy or microalbuminuria. *PLoS One* 2015;10:e0123517.
- 23 Schiano Lomoriello D, Abicca I, Parravano M, *et al.* Early alterations of corneal subbasal plexus in uncomplicated type 1 diabetes patients. *J Ophthalmol* 2019;2019:9818217.
- 24 Srinivasan S, Dehghani C, Pritchard N, *et al.* Corneal and retinal neuronal degeneration in early stages of diabetic retinopathy. *Invest Ophthalmol Vis Sci* 2017;58:6365–73.
- 25 Jiang M-S, Yuan Y, Gu Z-X, *et al.* Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. *Br J Ophthalmol* 2016;100:9–14.
- 26 Gad H, Petropoulos IN, Khan A, *et al.* Corneal confocal microscopy for the diagnosis of diabetic peripheral neuropathy: a systematic review and meta-analysis. *J Diabetes Investig* 2022;13:134–47.
- 27 Ahmed A, Bril V, Orszag A, *et al.* Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. *Diabetes Care* 2012;35:821–8.
- 28 Alam U, Jeziorska M, Petropoulos IN, *et al.* Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. *PLoS One* 2017;12:e0180175.
- 29 Hertz P, Bril V, Orszag A, *et al.* Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. *Diabet Med* 2011;28:1253–60.
- 30 Kalteniece A, Ferdousi M, Azmi S, *et al.* Keratocyte density is reduced and related to corneal nerve damage in diabetic neuropathy. *Invest Ophthalmol Vis Sci* 2018;59:3584–90.
- 31 Perkins BA, Lovblom LE, Bril V, *et al.* Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. *Diabetologia* 2018;61:1856–61.
- 32 Messmer EM, Schmid-Tannwald C, Zapp D, *et al.* In vivo confocal microscopy of corneal small fiber damage in diabetes mellitus. *Graefes Arch Clin Exp Ophthalmol* 2010;248:1307–12.
- 33 Rosenberg ME, Tervo TM, Immonen IJ, *et al.* Corneal structure and sensitivity in type 1 diabetes mellitus. *Invest Ophthalmol Vis Sci* 2000;41:2915–21.
- 34 Lagali NS, Allgeier S, Guimarães P, *et al.* Reduced corneal nerve fiber density in type 2 diabetes by wide-area mosaic analysis. *Invest Ophthalmol Vis Sci* 2017;58:6318–27.
- 35 Patel DV, McGhee CNJ. Mapping of the normal human corneal sub-basal nerve plexus by in vivo laser scanning confocal microscopy. *Invest Ophthalmol Vis Sci* 2005;46:4485–8.
- 36 Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease. *Surv Ophthalmol* 2014;59:263–85.
- 37 Lagali NS, Allgeier S, Guimarães P, *et al.* Wide-field corneal subbasal nerve plexus mosaics in age-controlled healthy and type 2 diabetes populations. *Sci Data* 2018;5:180075.
- 38 Vagenas D, Pritchard N, Edwards K, *et al.* Optimal image sample size for corneal nerve morphometry. *Optom Vis Sci* 2012;89:812–7.
- 39 Badian RA, Utheim TP, Lagali N. Region of interest and directional analysis of subbasal nerves in wide-area corneal nerve plexus mosaics in type 2 diabetes mellitus. *Sci Rep* 2020;10:10802.
- 40 Herrera-Pereda R, Taboada Crispi A, Babin D, *et al.* A review on digital image processing techniques for in-vivo confocal images of the cornea. *Med Image Anal* 2021;73:102188.
- 41 Peters MDJ, Marnie C, Tricco AC, *et al.* Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth* 2020;18:2119–26.
- 42 Tricco AC, Lillie E, Zarin W, *et al.* PRISMA extension for scoping reviews (PRISMA-scr): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- 43 Rayyan, intelligent systematic review. Available: https://rayyan.ai/cite?_ga=2.207442643.1192577048.1666769984-1889321050.1643312745 [Accessed 26 Oct 2022].